Esperion Therapeutics ESPR Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's cash & equivalents?
- Esperion Therapeutics (ESPR) reported cash & equivalents of $156.16M in Q1 2026.
- How has Esperion Therapeutics's cash & equivalents changed year-over-year?
- Esperion Therapeutics's cash & equivalents increased by 36.2% year-over-year, from $114.63M to $156.16M.
- What is the long-term trend for Esperion Therapeutics's cash & equivalents?
- Over 5 years (2020 to 2025), Esperion Therapeutics's cash & equivalents has grown at a -11.3% compound annual growth rate (CAGR), from $304.96M to $167.85M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.